Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting
PR Newswire - Mon Jun 01, 10:00AM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." The data was presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. The poster is available today on the website http://fennecpharma.com/investors/presentations-events/.
FRX.TO: 2.77 (-0.29)
Fennec Announces Presentation of Positive Interim Sodium Thiosulfate Phase III Safety Data at the 2015 ASCO Annual Meeting
Marketwired - Sun May 31, 8:01PM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX) (OTCQB: FENCF), announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." The data was presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. The poster is available today on the website http://fennecpharma.com/investors/presentations-events/.
FRX.TO: 2.77 (-0.29)
Fennec to Present at the Jefferies 2015 Global Healthcare Conference
Marketwired - Fri May 29, 5:01AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that it will present at the Jefferies 2015 Global Healthcare Conference being held in New York City. Rosty Raykov, CEO, will provide an overview of the Company's business on Tuesday, June 2, 2015 at 11:30 a.m. (ET).
FRX.TO: 2.77 (-0.29)
Fennec Announces Results of Annual Meeting
Marketwired - Thu May 28, 7:29PM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated April 23, 2015 (the "Circular"
FRX.TO: 2.77 (-0.29)
Fennec Provides Corporate Update and First Quarter Ended March 31, 2015 Financial Results
Marketwired - Fri May 15, 6:01AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate developments and financial results for the first quarter ended March 31, 2015.
FRX.TO: 2.77 (-0.29)
Fennec Announces Availability of Siopel 6 Study Abstract for ASCO 2015 Meeting
Marketwired - Thu May 14, 5:01AM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF), today announced that sodium thiosulfate (STS) will be featured in the abstract titled "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." at the American Society of Clinical Oncology (ASCO) being held May 29 through June 2, 2014 in Chicago, IL. The abstract is available as of today on the website http://www.abstract.asco.org/.
FRX.TO: 2.77 (-0.29)
Fennec Pharmaceuticals Announces the Exercise of Warrants by the Company's Largest Shareholder and Provides Updated Corporate Capital Structure
Marketwire Canada - Mon May 04, 6:17AM CDT
Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today reported that Southpoint Master Fund, LP ("Southpoint"
FRX.TO: 2.77 (-0.29)
Southpoint Files Early Warning Report in Connection With Exercise of Warrants in Fennec Pharmaceuticals Inc.
Marketwired - Wed Apr 29, 12:32PM CDT
Southpoint Master Fund, LP ("Southpoint"
Fennec Pharmaceuticals Provides Corporate Update and Fiscal Year Ended December 31, 2014 Financial Results
Marketwired - Wed Apr 01, 6:31AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a clinical stage biopharmaceutical company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2014. All amounts are in US dollars unless otherwise specified.
FRX.TO: 2.77 (-0.29)
Fennec Pharmaceuticals Announces That the Independent Data Monitoring Committee (IDMC) Recommends the Continuation of SIOPEL 6 Phase 3 Clinical Trial
Marketwired - Mon Feb 02, 7:02AM CST
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, announced that the IDMC overseeing the SIOPEL 6 phase 3 clinical trial recommended that the study be continued as planned. The IDMC has been established to assess any potential concern of an adverse effect of STS on the efficacy of the cisplatin chemotherapy and to review safety according to protocol pre-specified patient numbers. Previously, the IDMC reached similar conclusion after reviewing the safety of 20, 40, 60 and 80 patients and their current recommendation on 100 patients to continue the clinical trial represents the last and final safety review.
FRX.TO: 2.77 (-0.29)
Fennec Pharmaceuticals Announces Completion of Patient Enrollment in Sodium Thiosulfate Phase 3 SIOPEL 6 Study
Marketwired - Mon Jan 05, 8:03AM CST
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), today reported the second sodium thiosulfate Phase 3 study, conducted by the International Childhood Liver Tumour Strategy Group, SIOPEL 6, has fully enrolled and is now closed for recruitment. One hundred and sixteen patients in 46 clinical centers from 12 countries participated in the study.
FRX.TO: 2.77 (-0.29)